As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

It puts CARVYKTI in the enviable position of providing patients with longer lives, what some call the holy grail of oncology ...

Most of the switching is from patients on PD-1 monotherapy, where clinical data shows a more than doubling in progression-free survival ... and started a phase 3 trial in colorectal cancer last ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Try out other networks if you're looking for a cheaper carrier or want to downsize your plan. AT&T's Cricket Wireless and ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

AT&T, T-Mobile, and Verizon offer free trials with eSIM, so you can see if the network is a good fit where you live without compromising your current coverage. T-Mobile's Network Pass was one of ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...